The VOYAGER study

In a Phase 2 dose-ranging study, VYZULTA significantly outperformed Xalatan (latanoprost) 0.005% in mean diurnal IOP reduction from baseline at Day 28.1

34.6%

mean IOP reduction from baseline1

blue down-facing arrow showing 9.0-mmHg IOP reduction with VYZULTA® gray down-facing arrow showing 7.8-mmHg IOP reduction with Xalatanblue down-facing arrow showing 9.0-mmHg IOP reduction with VYZULTA® gray down-facing arrow showing 7.8-mmHg IOP reduction with Xalatan

29.8%

mean IOP reduction from baseline1

(P=0.005)

Baseline mean diurnal IOP was 26.01 mmHg and 26.15 mmHg for VYZULTA (n=83) and Xalatan (n=82), respectively.1
STUDY DESIGN

In a post hoc analysis, a high proportion of VYZULTA patients achieved additional IOP reductions beyond the Xalatan mean of 7.8 mmHg at Day 28.1,2

Many VYZULTA patients achieved multiple-mmHg IOP reductions beyond Xalatan at Day 28.

For example, 30% of VYZULTA patients had a 3-mmHg or greater reduction beyond the Xalatan mean—in other words, a 10.8-mmHg reduction or greater.

Patients Achieving Additional mmHg Reductions Beyond Xalatan2
VYZULTA
Patients
right arrow
 Additional
mmHg
Reduction
42% ≥2
30% ≥3
19% ≥4
12% ≥5

The majority of VYZULTA-treated patients achieved IOP of ≤18 mmHg more consistently compared with those treated with Xalatan.1

second tab with data chart showing consistently more patients taking VYZULTA® at target IOP compared to Xalatan

Baseline mean diurnal IOP was 26.01 mmHg and 26.15 mmHg for VYZULTA (n=83) and Xalatan (n=82), respectively.1

STUDY DESIGN

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here to see full Prescribing Information.

References: 1. Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL; VOYAGER Study Group. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open-angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738-745. 2. Data on file. Bausch & Lomb Inc.

Expand

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent